^
Association details:
| Biomarker: | GOPC-ROS1 fusion + KRAS Q61H |
|---|---|
| Cancer: | Colorectal Cancer |
| Drug: | Xalkori (crizotinib) (ALK inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Frequency, molecular characteristics, and therapeutic targeting of ROS1 oncogenic fusions in colorectal cancer.
Published date:
01/18/2022
Excerpt:
We report disease course and treatment response of an index patient with chemotherapy-refractory right-sided metastatic CRC, harboring an activating ROS1 fusion (GOPC-ROS1)....After 15 months on crizotinib, disseminated tumor progression occurred, with KRAS Q61H emerging in tumor tissue (53.7% variant allele frequency (VAF)) and liquid biopsy (13.5% VAF).
DOI:
10.1200/JCO.2022.40.4_suppl.160
